Titan Pharmaceuticals, Inc. (TTNP)

USD 3.45

(0.29%)

Market Cap (In USD)

3.15 Million

Revenue (In USD)

184 Thousand

Net Income (In USD)

-5.56 Million

Avg. Volume

449.32 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.24-14.8
PE
-
EPS
-
Beta Value
1.125
ISIN
US8883147055
CUSIP
888314606
CIK
910267
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David Elliot Lazar
Employee Count
-
Website
https://www.titanpharm.com
Ipo Date
1996-01-18
Details
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.